We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.15%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$748M
Cap. Flow
-$582M
Cap. Flow %
-24.75%
Top 10 Hldgs %
32.94%
Holding
108
New
18
Increased
28
Reduced
25
Closed
23

Top Buys

1
CATX icon
Perspective Therapeutics
CATX
+$43.9M
2
CGEM icon
Cullinan Oncology
CGEM
+$33.2M
3
INCY icon
Incyte
INCY
+$30M
4
TMO icon
Thermo Fisher Scientific
TMO
+$24.9M
5
ARGX icon
argenx
ARGX
+$23.2M

Top Sells

1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$139M
2
ALGN icon
Align Technology
ALGN
+$62M
3
BSX icon
Boston Scientific
BSX
+$57.5M
4
LLY icon
Eli Lilly
LLY
+$54.5M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$46.6M

Sector Composition

1 Healthcare 99.8%
2 Technology 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
26
United Therapeutics
UTHR
$22.7B
$35M 1.49%
110,000
-107,000
-49% -$28.3M
INCY icon
27
Incyte
INCY
$23.4B
$32.1M 1.36%
+529,000
New +$30M
SGRY icon
28
Surgery Partners
SGRY
$2.09B
$31.1M 1.32%
1,306,477
-138,523
-10% -$3.55M
CATX icon
29
Perspective Therapeutics
CATX
$341M
$30.3M 1.29%
+3,037,668
New +$43.9M
AXSM icon
30
Axsome Therapeutics
AXSM
$11.8B
$30.3M 1.29%
376,000
-55,000
-13% -$4.07M
XENE icon
31
Xenon Pharmaceuticals
XENE
$6.6B
$29.4M 1.25%
754,000
+44,000
+6% +$1.76M
DXCM icon
32
DexCom
DXCM
$29.6B
$29.4M 1.25%
259,000
+82,100
+46% +$10.4M
RVMD icon
33
Revolution Medicines
RVMD
$39.6B
$29.3M 1.25%
755,000
+120,000
+19% +$4.49M
INSM icon
34
Insmed
INSM
$23.5B
$28.8M 1.22%
+430,000
New +$16.7M
ITCI
35
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$27.4M 1.16%
400,000
-200,000
-33% -$13.9M
CGEM icon
36
Cullinan Oncology
CGEM
$1.09B
$27.2M 1.16%
+1,559,826
New +$33.2M
GKOS icon
37
Glaukos
GKOS
$9.21B
$26.5M 1.13%
224,000
– –
NGNE icon
38
Neurogene
NGNE
$744M
$26.5M 1.13%
727,537
+262,300
+56% +$9.25M
ARGX icon
39
argenx
ARGX
$53.8B
$26M 1.11%
+60,500
New +$23.2M
MIRM icon
40
Mirum Pharmaceuticals
MIRM
$7.25B
$25M 1.06%
731,104
-411,746
-36% -$10.8M
ESTA icon
41
Establishment Labs
ESTA
$2.72B
$24.1M 1.03%
531,000
+306,000
+136% +$15.5M
IMVT icon
42
Immunovant
IMVT
$8.27B
$24M 1.02%
908,000
+403,000
+80% +$11.5M
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$376M
$23.7M 1.01%
1,100,000
+75,000
+7% +$1.72M
LNTH icon
44
Lantheus
LNTH
$7B
$23.3M 0.99%
290,000
-190,000
-40% -$13.9M
PCVX icon
45
Vaxcyte
PCVX
$8.12B
$21.4M 0.91%
284,000
– –
APGE icon
46
Apogee Therapeutics
APGE
$10.1B
$19.2M 0.81%
487,000
+102,107
+27% +$4.96M
JSPR icon
47
Jasper Therapeutics
JSPR
$24.8M
$17.8M 0.75%
782,000
+22,000
+3% +$528K
NMRA icon
48
Neumora Therapeutics
NMRA
$298M
$17.7M 0.75%
1,800,000
– –
LEGN icon
49
Legend Biotech
LEGN
$4.31B
$17.6M 0.75%
398,000
-270,300
-40% -$12.5M
GILD icon
50
Gilead Sciences
GILD
$167B
$17.5M 0.74%
+255,000
New +$17M
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
CM
Columbus Macro New Castle, Pennsylvania $936M AUM 12.9% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return

Avidity Partners Management's Q2 2024 Portfolio in Review

As of Q2 2024, Avidity Partners Management held 108 positions worth $2.35B, down 24% from $3.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $582M in Q2 2024, closing 23 positions and reducing 25 holdings. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in Perspective Therapeutics worth $30.3M.

  • Avidity Partners Management's largest Q2 2024 buy was Perspective Therapeutics: 3,037,668 shares worth $30.3M.
  • Avidity Partners Management added most to Thermo Fisher Scientific in Q2 2024, an estimated $24.9M increase.
  • Avidity Partners Management's biggest Q2 2024 reduction was Boston Scientific, cutting an estimated $57.5M.
  • Avidity Partners Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $139M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.35B portfolio in Q2 2024.
  • Avidity Partners Management opened 18 new positions and closed 23 in Q2 2024.
  • Avidity Partners Management's portfolio value fell 24% quarter-over-quarter to $2.35B.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.